Cue Biopharma
CUE
60 hedge funds and large institutions have $35.1M invested in Cue Biopharma in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 15 closing their positions.
168% more call options, than puts
Call options by funds: $201K | Put options by funds: $75K
22% more capital invested
Capital invested by funds: $28.7M → $35.1M (+$6.4M)
0.25% less ownership
Funds ownership: 1.21% → 0.95% (-0.25%)
6% less funds holding
Funds holding: 64 → 60 (-4)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$2.8M |
| 2 |
BL
Bleichroeder LP
New York
|
+$934K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$934K |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$899K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$2.41M |
| 2 |
Renaissance Technologies
New York
|
-$867K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$518K |
| 4 |
E
Ergoteles
New York
|
-$261K |
| 5 |
AC
Apogem Capital
New York
|
-$247K |
CUE Hedge Fund Activity: Q4 2022 in Review
60 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2022, worth a combined $35.1M — up 22% from $28.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CUE and 12 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Slate Path Capital, adding an estimated $2.8M. The largest seller was Sanders Morris Harris, cutting an estimated $2.41M.
- 60 institutional investors held Cue Biopharma (CUE) as of Q4 2022, down from 64 in Q3 2022.
- Funds reported $35.1M of Cue Biopharma stock for Q4 2022, up 22% quarter-over-quarter.
- 12 funds opened new Cue Biopharma positions in Q4 2022 and 15 closed out, a net change of -3 holders.
- The largest Cue Biopharma buyer in Q4 2022 was Slate Path Capital, an estimated $2.8M added.
- The largest Cue Biopharma seller in Q4 2022 was Sanders Morris Harris, an estimated $2.41M sold.
Based on aggregated 13F filings for Q4 2022.